These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24060868)

  • 1. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.
    Gottwein JM; Jensen SB; Serre SB; Ghanem L; Scheel TK; Jensen TB; Krarup H; Uzcategui N; Mikkelsen LS; Bukh J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6034-49. PubMed ID: 24060868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
    Gottwein JM; Scheel TK; Jensen TB; Ghanem L; Bukh J
    Gastroenterology; 2011 Sep; 141(3):1067-79. PubMed ID: 21699793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
    Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.
    Pham LV; Ramirez S; Carlsen THR; Li YP; Gottwein JM; Bukh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive mutation F772S-enhanced p7-NS4A cooperation facilitates the assembly and release of hepatitis C virus and is associated with lipid droplet enlargement.
    Duan X; Anwar MI; Xu Z; Ma L; Yuan G; Chen Y; Liu X; Xia J; Zhou Y; Li YP
    Emerg Microbes Infect; 2018 Aug; 7(1):143. PubMed ID: 30087320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
    Imhof I; Simmonds P
    J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.
    Scheel TK; Gottwein JM; Carlsen TH; Li YP; Jensen TB; Spengler U; Weis N; Bukh J
    J Virol; 2011 Mar; 85(6):2891-906. PubMed ID: 21177811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
    Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A.
    Gottwein JM; Jensen TB; Mathiesen CK; Meuleman P; Serre SB; Lademann JB; Ghanem L; Scheel TK; Leroux-Roels G; Bukh J
    J Virol; 2011 Sep; 85(17):8913-28. PubMed ID: 21697486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.
    Li YP; Ramirez S; Gottwein JM; Scheel TK; Mikkelsen L; Purcell RH; Bukh J
    Proc Natl Acad Sci U S A; 2012 May; 109(18):E1101-10. PubMed ID: 22467829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.
    Gottwein JM; Scheel TK; Jensen TB; Lademann JB; Prentoe JC; Knudsen ML; Hoegh AM; Bukh J
    Hepatology; 2009 Feb; 49(2):364-77. PubMed ID: 19148942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
    Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
    Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
    Ramirez S; Li YP; Jensen SB; Pedersen J; Gottwein JM; Bukh J
    Hepatology; 2014 Feb; 59(2):395-407. PubMed ID: 23913364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.
    Scheel TK; Prentoe J; Carlsen TH; Mikkelsen LS; Gottwein JM; Bukh J
    PLoS Pathog; 2012; 8(5):e1002696. PubMed ID: 22654662
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexes.
    Yang W; Sun Y; Hou X; Zhao Y; Fabrycki J; Chen D; Wang X; Agarwal A; Phadke A; Deshpande M; Huang M
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3168-77. PubMed ID: 23629709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.
    Scheel TK; Gottwein JM; Jensen TB; Prentoe JC; Hoegh AM; Alter HJ; Eugen-Olsen J; Bukh J
    Proc Natl Acad Sci U S A; 2008 Jan; 105(3):997-1002. PubMed ID: 18195353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
    Kuntzen T; Timm J; Berical A; Lennon N; Berlin AM; Young SK; Lee B; Heckerman D; Carlson J; Reyor LL; Kleyman M; McMahon CM; Birch C; Schulze Zur Wiesch J; Ledlie T; Koehrsen M; Kodira C; Roberts AD; Lauer GM; Rosen HR; Bihl F; Cerny A; Spengler U; Liu Z; Kim AY; Xing Y; Schneidewind A; Madey MA; Fleckenstein JF; Park VM; Galagan JE; Nusbaum C; Walker BD; Lake-Bakaar GV; Daar ES; Jacobson IM; Gomperts ED; Edlin BR; Donfield SM; Chung RT; Talal AH; Marion T; Birren BW; Henn MR; Allen TM
    Hepatology; 2008 Dec; 48(6):1769-78. PubMed ID: 19026009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.